This article was downloaded by: [Dalhousie University] On: 26 December 2014, At: 11:14 Publisher: Taylor & Francis Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK

Human Vaccines & Immunotherapeutics Publication details, including instructions for authors and subscription information: http://www.tandfonline.com/loi/khvi20

Alzheimer disease immunotherapeutics: Then and now a

a

a

a

Harashish Jindal , Bhumika Bhatt , Shashikantha Sk & Jagbir Singh Malik a

Department of Community Medicine; Pt BD Sharma PGIMS; Rohtak, Haryana, India Published online: 31 Oct 2014.

Click for updates To cite this article: Harashish Jindal, Bhumika Bhatt, Shashikantha Sk & Jagbir Singh Malik (2014) Alzheimer disease immunotherapeutics: Then and now, Human Vaccines & Immunotherapeutics, 10:9, 2741-2743, DOI: 10.4161/21645515.2014.970959 To link to this article: http://dx.doi.org/10.4161/21645515.2014.970959

PLEASE SCROLL DOWN FOR ARTICLE Taylor & Francis makes every effort to ensure the accuracy of all the information (the “Content”) contained in the publications on our platform. However, Taylor & Francis, our agents, and our licensors make no representations or warranties whatsoever as to the accuracy, completeness, or suitability for any purpose of the Content. Any opinions and views expressed in this publication are the opinions and views of the authors, and are not the views of or endorsed by Taylor & Francis. The accuracy of the Content should not be relied upon and should be independently verified with primary sources of information. Taylor and Francis shall not be liable for any losses, actions, claims, proceedings, demands, costs, expenses, damages, and other liabilities whatsoever or howsoever caused arising directly or indirectly in connection with, in relation to or arising out of the use of the Content. This article may be used for research, teaching, and private study purposes. Any substantial or systematic reproduction, redistribution, reselling, loan, sub-licensing, systematic supply, or distribution in any form to anyone is expressly forbidden. Terms & Conditions of access and use can be found at http:// www.tandfonline.com/page/terms-and-conditions

COMMENTARY Human Vaccines & Immunotherapeutics 10:9, 2741--2743; September 2014; Published with license by Taylor & Francis Group, LLC

Alzheimer disease immunotherapeutics Then and now Harashish Jindal*, Bhumika Bhatt, Shashikantha Sk, and Jagbir Singh Malik Department of Community Medicine; Pt BD Sharma PGIMS; Rohtak, Haryana, India

Downloaded by [Dalhousie University] at 11:14 26 December 2014

D

Keywords: Alzheimer disease, vaccine, immunotherapeutics, Abeta42, solanezumab © Harashish Jindal, Bhumika Bhatt, Shashikantha Sk, and Jagbir Singh Malik *Correspondence to: Harashish Jindal; Email: harry8723@ gmail.com Submitted: 05/23/2014 Accepted: 06/03/2014 http://dx.doi.org/10.4161/21645515.2014.970959 www.landesbioscience.com

ementia is a public health priority and one of the major contributors to morbidity and global non-communicable disease burden, thus necessitating the need for significant health-care interventions. Alzheimer disease (AD) is the most common cause of dementia and may contribute to 60–70% of cases. The cause and progression of AD are not well understood but have been thought to be due at least in part to protein misfolding (proteopathy) manifest as plaque accumulation of abnormally folded bamyloid and tau proteins in brain. There are about 8 million new cases per year. The total number of people with dementia is projected to almost double every 20 years, to 66 million in 2030 and 115 million in 2050. Immunotherapy in AD aimed at b-amyloid covers 2 types of vaccination: active vaccination against Ab42 in which patients receive injections of the antigen itself, or passive vaccination in which patients receive injections of monoclonal antibodies (mAb) against Ab42. Three of the peptide vaccines for active immunizations, CAD106, ACC001, and Affitope, are in phase 2 clinical trials. Three of the mAbs solanezumab, gantenerumab, and crenezumab, are or were in phase 2 and 3 clinical studies. While the phase 3 trials failed, one of these may have shown a benefit at least in mild forms of AD. There is a need for a greater initiative in the development of immunotherapeutics. Several avenues have been explored and still to come.

Introduction Dementia is a public health priority and one of the major contributors to Human Vaccines & Immunotherapeutics

global morbidity and non-communicable disease burden, thus necessitating the need for health-care interventions. It is a syndrome that affects memory, thinking, behavior and ability to perform everyday activities. Not only it is overwhelming for those who have it, but also for their caregivers and families, and the lack of awareness and understanding in most countries results in social labeling, barriers to diagnosis and care which affects caregivers, families, and societies physically, psychologically, and economically.1 AD is the most common cause of dementia and may contribute to 60–70% of cases of dementia.2 AD was first described in 1906 by German psychiatrist and neuro-pathologist Alois Alzheimer.3 It affects all age groups with higher prevalence in >65-y-old people, and is predicted to affect 1 in 85 people globally by 2050.4 Although clinical manifestations of AD differ for every individual, there are many common symptoms. In the early stages, it affects short-term memory and thinking ability, and as the disease advances it includes confusion, irritability, aggression, mood swings, trouble with language, and long-term memory. Bodily functions are gradually lost, ultimately leading to death. The average life expectancy following diagnosis is »7 y.5 Fewer than 3% of individuals live >14 y after diagnosis.6 The causes and progression of AD are not well understood but have been thought to be due in part to protein misfolding (proteopathy) caused by the accumulation of abnormally folded b-amyloid in plaques and tau protein tangles in the brain. The disease, which has been found to be associated with plaques and tangles in the brain, has no cure and available treatments offer relatively small 2741

symptomatic benefit while remaining palliative in nature. Current treatments can be divided into pharmaceutical, psychosocial, and caregiving. Five drugs are used to treat the symptoms of cognitive problems of AD: four are acetylcholinesterase inhibitors (tacrine, rivastigmine, galantamine, and donepezil) and the other (memantine) is an NMDA receptor antagonist. The benefit from their use is small.7 No medication has been shown to delay or halt the progression of the disease.

Downloaded by [Dalhousie University] at 11:14 26 December 2014

Global Burden of Disease The current burden and future impact of the dementia epidemic has been underestimated, particularly for the East Asian and Sub-Saharan African regions. This is a global epidemic—although cases are disproportionately concentrated in the world’s richest and most demographically aged countries, the majority (58%) of people with dementia live in low- and middleincome countries where access to social protection, services, support, and care are very limited. Worldwide, 36 million people have dementia, with »8 million new cases annually. The number of people with dementia is projected to almost double to 66 million in 2030 and 115 million in 2050. Much of this increase is attributable to the rising numbers of people with dementia living in low- and middleincome countries.2 It has been estimated that 5.2 million Americans have AD, of which 4% people are younger than 65 y. An addition 10 million additional people in the US are projected to develop AD in the baby-boom generation.8 The global economic cost of dementia in 2010 was estimated to be $604 billion D 1% of global GDP. Costs are expected to escalate proportionately with the numbers of affected individuals and with increased demand for care services, particularly in low- and middle-income countries.9

Immunotherapeutics Research has investigated several avenues to attack AD, of which vaccination/

2742

immunotherapy is one of the most popular. Immunotherapy in AD covers 2 types of vaccination: active vaccination against Ab42 in which patients receive injections of the antigen itself, or passive vaccination in which patients receive injections of anti-Ab mAbs.

ACImmune-35 (ACI-35) vaccine is designed to stimulate the production of antibodies targeting the tau protein that forms fibers and tangles in the brain. ACI35 is in a phase 1/2a clinical trial to clear such structures, another hallmark of the fatal brain-wasting disease.15

Passive Immunotherapeutics Active Immunotherapeutics Beka Solomon’s lab first suggested in the mid-1990s that anti-Ab mAb could be used to prevent Ab fibril formation and disaggregate pre-formed fibrils and plaque.10 Schenk and colleagues then published results on active Ab1–42 peptide immunization in APP/PS1 double transgenic mice as an AD mouse model, which showed s reduction in Ab levels in the brains of the treated mice as well as improvements in memory tasks.11 The first active vaccine clinical trial for AD, AN1792, was halted early in 2002 due to the development of meningoencephalitis in »6% (18 of 300) of the enrolled moderate-to-severe AD patients.12 In the view of potentially dangerous autoimmune/inflammatory responses caused by newly activated Ab-specific inflammatory T cells, new peptide vaccines were designed in which the sequences responsible for T-cell activation were deleted and only the parts needed for generation of Ab-specific antibodies remained. Three such peptide vaccines for active immunizations, CAD106, ACC001, and Affitope. Phase 1 trials for each of these 3 vaccines showed specific antibody responses with no signs of adverse autoimmune inflammation, and these active immunization are continuing in phase 2 clinical trials.13 A randomized clinical trial in Sweden of CAD106 showed that the majority of subjects reported adverse events with nasopharyngitis and injection site erythema as the 2 most common adverse effects while 67–82% of subjects in the 2 cohorts developed anti-Ab antibody responses, suggesting that CAD106 has a favorable safety profile and acceptable antibody response in subjects with AD.14 Further research is needed to confirm safety and to attempt to establish the efficacy of CAD106.

Human Vaccines & Immunotherapeutics

Another approach employs humanized anti-Ab mAbs that are injected as passive immunization therapy. Three such mAbs, solanezumab, gantenerumab, and crenezumab, have been in phase 2 and 3 clinical studies.13 Bapineuzemab was the first mAb to be used as passive immunotherapy in AD patients but was discontinued after phase 3 trials since it failed to achieve any efficacy. Solanezumab failed its primary outcome in a phase 3 trials but did show benefits in at least in mild forms of AD, and is in a new phase 3 trial in a defined cohort of early-stage disease subjects.

Challenges Only a small percentage of antibodies cross the blood brain barrier in normal subjects (»0.1%), with a somewhat higher percentage in AD subjects (0.5–1.0%); thus, it may be useful to find ways to improve antibody penetration into brain. Active vaccination requires particular attention to immune effects of immunotherapy, including immunosenescence in the elderly, the potential for autoimmune effects when vaccinating against self-proteins, and the use of strong, pro-inflammatory adjuvants. Removing amyloid after neurons have been lost has not been effective thus far, suggesting that treatment should be started earlier and perhaps tested over longer periods of time.16

Conclusion Dementia is a public health priority, and AD is one of the most common causes. There is a need for a greater initiative in the development of immunotherapeutics. Several avenues have been explored and are still to come. Results to

Volume 10 Issue 9

date have been mixed, and there still a long road ahead for an effective treatment of this debilitating disease. Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Downloaded by [Dalhousie University] at 11:14 26 December 2014

References 1. World Health Organization and Alzheimer’s Disease International. Dementia: A Public Health Priority. Geneva: World Health Organization; 2012. [Accessed on 30 April 2014]. Available from http://www.who.int/ mental_health/publications/dementia_report_2012/en/ 2. Factsheet.Dementia.World Health organization.2012 April. [Accessed on 02 May 2014]. Available from: http://www.who.int/mediacentre/factsheets/fs362/en/ 3. Berchtold NC, Cotman CW. Evolution in the conceptualization of dementia and Alzheimer’s disease: GrecoRoman period to the 1960s. Neurobiol Aging 1998; 19:173-89; PMID:9661992; http://dx.doi.org/ 10.1016/S0197-4580(98)00052-9 4. Brookmeyer R, Johnson E, Ziegler-Graham K, Arrighi HM. Forecasting the global burden of Alzheimer’s disease. Alzheimers Dement 2007; 3:186-91; PMID:19595937; http://dx.doi.org/10.1016/j. jalz.2007.04.381

www.landesbioscience.com

5. M€ols€a PK, Marttila RJ, Rinne UK. Survival and cause of death in Alzheimer’s disease and multi-infarct dementia. Acta Neurol Scand 1986; 74:103-7; PMID:3776457; http://dx.doi.org/10.1111/j.16000404.1986.tb04634.x 6. M€ols€a PK, Marttila RJ, Rinne UK. Long-term survival and predictors of mortality in Alzheimer’s disease and multi-infarct dementia. Acta Neurol Scand 1995; 91:159-64; PMID:7793228; http://dx.doi.org/ 10.1111/j.1600-0404.1995.tb00426.x 7. Pohanka M. Cholinesterases, a target of pharmacology and toxicology. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2011; 155:219-29; PMID:22286807 8. Alzheimer’s Association. 2013 Alzheimer’s disease facts and figures. Alzheimer’s & Dementia. 2013 Mar 9 (2).208-45. [Accessed on 01st May 2014]. Available from: http://www.sciencedirect.com/science/article/pii/ S1552526013000769 9. Alzheimer’s Disease International. Policy brief: the global impact of dementia 2013–2050. Alzheimer’s Disease International, London. 2013 December. [Accessed on 12th May 2014]. Available from http:// www.alz.co.uk/research/G8-policy-brief 10. Solomon B, Koppel R, Hanan E, Katzav T. Monoclonal antibodies inhibit in vitro fibrillar aggregation of the Alzheimer b-amyloid peptide. Proc Natl Acad Sci U S A 1996; 93:452-5; PMID:8552659; http://dx.doi.org/ 10.1073/pnas.93.1.452 11. Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K, et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse.

Human Vaccines & Immunotherapeutics

12.

13.

14.

15.

16.

Nature 1999; 400:173-7; PMID:10408445; http://dx. doi.org/10.1038/22124 Gilman S, Koller M, Black RS, Jenkins L, Griffith SG, Fox NC, Eisner L, Kirby L, Rovira MB, Forette F, et al.; AN1792(QS-21)-201 Study Team. Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology 2005; 64:1553-62; PMID:15883316; http://dx.doi.org/ 10.1212/01.WNL.0000159740.16984.3C Lambracht-Washington D, Rosenberg RN. Advances in the development of vaccines for Alzheimer’s disease. Discov Med 2013; 15:319-26; PMID:23725605 Winblad B, Andreasen N, Minthon L, Floesser A, Imbert G, Dumortier T, Maguire RP, Blennow K, Lundmark J, Staufenbiel M, et al. Safety, tolerability, and antibody response of active Ab immunotherapy with CAD106 in patients with Alzheimer’s disease: randomised, double-blind, placebo-controlled, first-inhuman study. Lancet Neurol 2012; 11:597-604; PMID:22677258; http://dx.doi.org/10.1016/S14744422(12)70140-0 Thomson Reuters. Swiss biotech firm starts new Alzheimer vaccine trial. United States:thomsonreuters;2014 [Accessed on 14 May 2014] Available from: http://www.reuters.com/article/2014/01/09/ alzheimers-acimmune-idUSL6N0KJ2QR20140109 Lemere CA. Immunotherapy for Alzheimer’s disease: hoops and hurdles. Mol Neurodegener 2013; 8:36; PMID:24148220; http://dx.doi.org/10.1186/17501326-8-36

2743

Alzheimer disease immunotherapeutics: then and now.

Dementia is a public health priority and one of the major contributors to morbidity and global non-communicable disease burden, thus necessitating the...
91KB Sizes 0 Downloads 11 Views